Rodrigo Dienstmann, MD

Rodrigo Dienstmann, MD

Principal Investigator, Oncology Data Science (ODysSey) Group
Vall d'Hebron Institute of Oncology
Barcelona, Spain
Computational Oncology Group
Sage Bionetworks
Seattle, Washington, USA

Related Videos

Based on the GENIE Consortium Project, what percentage of patients is estimated to be eligible for targeted therapy within the framework of precision cancer medicine, when evaluated with NGS? Video

Based on the GENIE Consortium Project, what percentage of patients is estimated to be eligible for targeted therapy within the framework of precision cancer medicine, when evaluated with NGS?

Based on the results of the GENIE Consortium Project, what percentage of patients is estimated to be eligible for targeted therapy within the framework of precision cancer medicine, when evaluated with NGS?

What are the translational implications for NGS as you understand it from the results of the AACR/MSK GENIE Consortium project recently reported in Cancer Discovery? Video

What are the translational implications for NGS as you understand it from the results of the AACR/MSK GENIE Consortium project recently reported in Cancer Discovery?

What are the translational implications for NGS as you understand it from the results of the AACR/MSK GENIE Consortium project recently reported in Cancer Discovery?

What have we learned from the GENIE Consortium Project about discrepancies between mutational profiles identified in the TCGA database versus those identified by NGS in the GENIE project? Video

What have we learned from the GENIE Consortium Project about discrepancies between mutational profiles identified in the TCGA database versus those identified by NGS in the GENIE project?

What have we learned from the GENIE Consortium Project about discrepancies between mutational profiles identified in primary tumors comprising the TCGA database versus those observed in distributions identified by NGS in the GENIE project ...

What is the role of NGS, and role of fusion detection, in particular, in wild type EGFR NSCLC, non-squamous head and neck cancer, and glioblastoma? Video

What is the role of NGS, and role of fusion detection, in particular, in wild type EGFR NSCLC, non-squamous head and neck cancer, and glioblastoma?

What is the role of NGS, and role of fusion detection, in particular, in wild type EGFR NSCLC, non-squamous head and neck cancer, and glioblastoma?

How is NGS altering our understanding of the importance of combining, aggregating, and analyzing a full range of genomic data to guide therapeutic decisions, especially in rare tumor types? Video

How is NGS altering our understanding of the importance of combining, aggregating, and analyzing a full range of genomic data to guide therapeutic decisions, especially in rare tumor types?

How is NGS altering our understanding of the importance of combining, aggregating, and analyzing a full range of genomic data — from single mutations and alterations to fusion genes, copy number and RNA expression data — to guide therapeutic ...

Considering the relationship between total mutational burden and responsiveness to immune checkpoint inhibition, how will hybrid capture-based whole exome NGS guide precision-based treatment? Video

Considering the relationship between total mutational burden and responsiveness to immune checkpoint inhibition, how will hybrid capture-based whole exome NGS guide precision-based treatment?

In light of increasing evidence suggesting a relationship between total mutational burden and responsiveness to immune checkpoint inhibition, how are you positioning the role of hybrid capture-based whole exome NGS to guide precision-based cancer treatment?

What is the evolving role of NGS in identifying targeted therapies in the setting of metastatic colorectal cancer, with a focus on BRAF mutations, HER2 amplification testing, and detection of microsatellite instability (MSI)? Video

What is the evolving role of NGS in identifying targeted therapies in the setting of metastatic colorectal cancer, with a focus on BRAF mutations, HER2 amplification testing, and detection of microsatellite instability (MSI)?

What is the evolving role of NGS in identifying targeted therapies in the setting of metastatic colorectal cancer? Can you discuss this with a focus on BRAF mutations, HER2 amplification testing, and detection of microsatellite instability ...

In what kinds of non-melanoma cancers does BRAF V600 appear to be a targetable oncogene? What do studies using BRAF V600 to guide vemurafenib and cetuximab in colorectal cancer show? (English) Video

In what kinds of non-melanoma cancers does BRAF V600 appear to be a targetable oncogene? What do studies using BRAF V600 to guide vemurafenib and cetuximab in colorectal cancer show? (English)

In what kinds of non-melanoma cancers does BRAF V600 appear to be a targetable oncogene? What do initial studies using BRAF V600 to guide vemurafenib and cetuximab in patients with colorectal cancer show? Can genomic profiling updates ...

Can targeted therapies based on NGS-based genomic alterations be employed after first-line failure? Are targeted, matched therapies late in a disease as successful as at time of presentation? (English) Video

Can targeted therapies based on NGS-based genomic alterations be employed after first-line failure? Are targeted, matched therapies late in a disease as successful as at time of presentation? (English)

Can targeted therapies based on NGS-based genomic alterations still be employed even after a patient has failed a first-line therapy? Are targeted, matched therapies late in the natural history of a patient’s disease as successful as using ...